Related Experiment Video

Updated: Dec 19, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.2K

Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19

Xiangyang Xie1, Yuanliang Jiang2, Yuan Zeng1

  • 1Department of Pharmacy, General Hospital of Central Theater of the PLA, Wuhan, China.

Antiviral Therapy
|June 5, 2020
PubMed

Insights

A novel lopinavir/ritonavir combination therapy shows promise for treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing coronavirus disease (COVID-19). This approach is needed due to inconsistent results from current treatments.

Area of Science:

  • Virology
  • Infectious Diseases
  • Pharmacology

Background:

  • The global COVID-19 pandemic, caused by SARS-CoV-2, lacks a standard therapeutic guideline due to the virus's severity and high infectivity.
  • Current treatments in China, such as ribavirin and interferon-α, show variable efficacy, highlighting the urgent need for novel antiviral strategies.

Observation:

  • This case report details the administration of a lopinavir/ritonavir-based combination antiviral regimen to a patient diagnosed with SARS-CoV-2 infection.
  • The patient's response to this specific combination therapy was monitored.

Findings:

  • The lopinavir/ritonavir combination was utilized as a therapeutic intervention for a patient with SARS-CoV-2.
  • This case provides preliminary data on the application of this regimen in a clinical setting.

Implications:

  • The findings suggest a potential alternative or adjunctive therapy for COVID-19 management.
  • Further clinical trials are warranted to establish the safety and efficacy of lopinavir/ritonavir-based regimens for SARS-CoV-2 infection.

More Related Videos

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.7K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.0K

Related Concept Videos

Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
380
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
422
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
49.0K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
662
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
736
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
14.4K